Pertuzumab plus trastuzumab and chemotherapy for Japanese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subgroup analysis of the JACOB trial

被引：0
|
作者：
Kohei Shitara
Hiroki Hara
Takaki Yoshikawa
Kazumasa Fujitani
Tomohiro Nishina
Ayumu Hosokawa
Takashi Asakawa
Satoe Kawakami
Kei Muro
机构：
[1] National Cancer Center Hospital East,Gastroenterology and Gastrointestinal Oncology
[2] Saitama Cancer Center,Department of Gastroenterology
[3] Kanagawa Cancer Center,Department of Gastrointestinal Surgery
[4] National Cancer Center Hospital,Department of Gastric Surgery
[5] Osaka General Medical Center,Department of Surgery
[6] National Hospital Organization Shikoku Cancer Center,Department of Gastrointestinal Medical Oncology
[7] University of Toyama,Department of Gastroenterology and Hematology, Faculty of Medicine
[8] University of Miyazaki Hospital,Department of Clinical Oncology
[9] Chugai Pharmaceutical Co.,Clinical Information and Intelligence Department
[10] Ltd,Clinical Science & Strategy Department
[11] Chugai Pharmaceutical Co.,Department of Clinical Oncology
[12] Ltd,undefined
[13] Aichi Cancer Center Hospital,undefined
来源：
International Journal of Clinical Oncology | 2020年 / 25卷
关键词：
Pertuzumab; Trastuzumab; Metastatic gastric cancer; Metastatic gastroesophageal junction cancer; Japanese subgroup analysis; Phase III;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：301 / 311
页数：10
相关论文
共 50 条
  • [41] Trastuzumab/Pertuzumab plus Radiochemotherapy for HER2-positive AEG Tumor
    Lichert, Frank
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2020, 58 (06): : 520 - +
  • [42] Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial
    Hurvitz, Sara A.
    Martin, Miguel
    Symmans, W. Fraser
    Jung, Kyung Hae
    Huang, Chiun-Sheng
    Thompson, Alastair M.
    Harbeck, Nadia
    Valero, Vicente
    Stroyakovskiy, Daniil
    Wildiers, Hans
    Campone, Mario
    Boileau, Jean-Francois
    Beckmann, Matthias W.
    Afenjar, Karen
    Fresco, Rodrigo
    Helms, Hans-Joachim
    Xu, Jin
    Lin, Yvonne G.
    Sparano, Joseph
    Slamon, Dennis
    LANCET ONCOLOGY, 2018, 19 (01): : 115 - 126
  • [43] Effect of pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer: A meta-analysis
    Tian, Tian
    Ye, Jing
    Zhou, Sihai
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2017, 55 (09) : 720 - 727
  • [44] Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients
    Sawaki, Masataka
    BREAST CANCER-TARGETS AND THERAPY, 2014, 6 : 37 - 41
  • [45] Trastuzumab Biosimilar (HLX02), Pertuzumab Plus Chemotherapy in Patients with HER2-Positive Metastatic Breast Cancer after Progression of Trastuzumab: A Prospective, Phase II Study
    Zhang, Ruyan
    Liu, Xiaoran
    Song, Guohong
    Zhang, Yan
    Li, Huiping
    CANCER RESEARCH AND TREATMENT, 2024, 56 (03): : 795 - 801
  • [46] Complete response after pertuzumab plus trastuzumab plus docetaxel in metastatic Her2-positive breast cancer patients: review of four cases
    Lai-Tiong, F.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2018, 39 (05) : 845 - 846
  • [47] Trastuzumab in HER2-Positive Metastatic Gastric Cancer Profile Report
    Croxtall, Jamie D.
    McKeage, Kate
    BIODRUGS, 2011, 25 (04) : 257 - 259
  • [48] TRASTUZUMAB WITH CHEMOTHERAPY IN UNTREATED HER2-POSITIVE ADVANCED OR METASTATIC GASTRIC CANCER: EFFICACY RESULTS FROM THE ToGA TRIAL
    Bang, Y.
    Kang, Y.
    Chung, H.
    Shen, L.
    Sawaki, A.
    Lordick, F.
    Hill, J.
    Lehle, M.
    Feyereislova, A.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2009, 20 : 11 - 11
  • [49] Efficacy of trastuzumab plus paclitaxel for HER2-positive gastroesophageal junction cancer that is refractory to S-1
    Setsuo Utsunomiya
    Takuya Kurimoto
    International Cancer Conference Journal, 2013, 2 (2) : 116 - 119
  • [50] Efficacy of trastuzumab plus paclitaxel for HER2-positive gastroesophageal junction cancer that is refractory to S-1
    Utsunomiya, Setsuo
    Kurimoto, Takuya
    INTERNATIONAL CANCER CONFERENCE JOURNAL, 2013, 2 (02): : 116 - 119
12345